Irish life sciences company Technopath Clinical Diagnostics has launched its diagnostic reagent kit, the i-plaq test.
The i-plaq test is a blood test using a single human-based serum calibrator and two levels of controls enabling a quick detection of enzymatic activity of lipoprotein-associated phospholipase A2 (Lp-PLA2).
The Lp-PLA2 is a vascular-specific inflammatory marker considered critical in the formation of rupture-prone plaque from a standard blood test.
Higher levels of Lp-PLA2 are indicative of the fact that the atherosclerotic plaque is more likely to rupture, causing blood clot that could result in cardiovascular disease (CVD) events.
The Lp-PLA2 has a risk ratio similar in magnitude to that of systolic blood pressure and non-HDL cholesterol.
The i-plaq test’s performance and ease of use is expected to improve the CVD risk assessment for patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataTechnopath Clinical Diagnostics CEO Malcolm Bell said: "We are very excited to announce the commercialisation of the i-plaqtest kit, a test that is both easy to use and reliable while generating high quality patient results at clinically significant ranges.
"This launch represents a significant development opportunity for our company as we target additional products for this large and growing new market segment."